The molecular pathology of thymic epithelial tumors (TETs) is largely unknown. Using array comparative genomic hybridization (CGH), we evaluated 59 TETs and identified recurrent patterns of copy number (CN) aberrations in different histotypes. GISTIC algorithm revealed the presence of 126 significant peaks of CN aberration, which included 13 cancer-related genes. Among these peaks, CN gain of BCL2 and CN loss of CDKN2A/B were the only genes in the respective regions of CN aberration and were associated with poor outcome. TET cell lines were sensitive to siRNA knockdown of the anti-apoptotic molecules BCL2 and MCL1. Gx15-070, a pan-BCL2 inhibitor, induced autophagy-dependent necroptosis in TET cells via a mechanism involving mTOR pathways, and inhibited TET xenograft growth. ABT263, an inhibitor of BCL2/BCL-XL/BCL-W, reduced proliferation in TET cells when administered in combination with sorafenib, a tyrosine kinase inhibitor able to downregulate MCL1. Immunohistochemistry on 132 TETs demonstrated that CN loss of CDKN2A correlated with lack of expression of its related protein p16INK4 and identified tumors with poor prognosis. The molecular markers BCL2 and CDKN2A may be of potential value in diagnosis and prognosis of TETs. Our study provides the first preclinical evidence that deregulated anti-apoptotic BCL2 family proteins may represent suitable targets for TET treatment. © 2012 Macmillan Publishers Limited.

Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors / I. Petrini, P.S. Meltzer, P.A. Zucali, J. Luo, C. Lee, A. Santoro, H.S. Lee, K.J. Killian, Y. Wang, M. Tsokos, M. Roncalli, S.M. Steinberg, Y. Wang, G. Giaccone. - In: CELL DEATH & DISEASE. - ISSN 2041-4889. - 3:7(2012), pp. e351.-e351.1.

Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors

M. Roncalli;GIACCONE, GIOVENALE
2012

Abstract

The molecular pathology of thymic epithelial tumors (TETs) is largely unknown. Using array comparative genomic hybridization (CGH), we evaluated 59 TETs and identified recurrent patterns of copy number (CN) aberrations in different histotypes. GISTIC algorithm revealed the presence of 126 significant peaks of CN aberration, which included 13 cancer-related genes. Among these peaks, CN gain of BCL2 and CN loss of CDKN2A/B were the only genes in the respective regions of CN aberration and were associated with poor outcome. TET cell lines were sensitive to siRNA knockdown of the anti-apoptotic molecules BCL2 and MCL1. Gx15-070, a pan-BCL2 inhibitor, induced autophagy-dependent necroptosis in TET cells via a mechanism involving mTOR pathways, and inhibited TET xenograft growth. ABT263, an inhibitor of BCL2/BCL-XL/BCL-W, reduced proliferation in TET cells when administered in combination with sorafenib, a tyrosine kinase inhibitor able to downregulate MCL1. Immunohistochemistry on 132 TETs demonstrated that CN loss of CDKN2A correlated with lack of expression of its related protein p16INK4 and identified tumors with poor prognosis. The molecular markers BCL2 and CDKN2A may be of potential value in diagnosis and prognosis of TETs. Our study provides the first preclinical evidence that deregulated anti-apoptotic BCL2 family proteins may represent suitable targets for TET treatment. © 2012 Macmillan Publishers Limited.
BCL2 anti-apoptotic family members; CDKN2A; comparative genomic hybridization; target therapy; thymic epithelial tumors; adult; aged; aged, 80 and over; algorithms; aniline compounds; animals; apoptosis regulatory proteins; autophagy; benzenesulfonates; cell line, tumor; cell proliferation; comparative genomic hybridization; cyclin-dependent kinase inhibitor p15; cyclin-dependent kinase inhibitor p16; DNA copy number variations; female; humans; male; mice; mice, nude; middle aged; Myeloid cell Leukemia sequence 1 protein; neoplasms, glandular and epithelial; niacinamide; phenylurea compounds; prognosis; protein kinase inhibitors; proto-oncogene proteins c-bcl-2; pyridines; pyrroles; RNA interference; RNA, small interfering; sulfonamides; TOR serine-threonine kinases; thymus neoplasms; transplantation, heterologous; bcl-X protein; cell biology; immunology; cancer research; cellular and molecular neuroscience; medicine (all)
Settore MED/06 - Oncologia Medica
CELL DEATH & DISEASE
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/252445
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 40
social impact